Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
This article was originally published in RPM Report
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
You may also be interested in...
Democrats always feared having the health care reform debate carrying over past August. Now it’s October. Media coverage of chaotic town hall meetings, intra-party disputes, and a united Republican opposition show how prescient the Democrats were to worry about debate after the summer holidays. Democrats are now starting to consider how they’ll vote on a fi nal bill. Here’s what it could look like if the legislation goes through the Congressional shortcut of budget reconciliation and includes a public plan.
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.